Koyfin Home > Directory > Health Care > Aquestive Therapeutics Inc > Long-Term Debt

Aquestive Therapeutics Inc Long-Term Debt Chart (AQST)

Aquestive Therapeutics Inc annual/quarterly Long-Term Debt from 2017 to 2018.
  • Aquestive Therapeutics Inc Long-Term Debt for the quarter ending December 12, 2018 was $43m a -4.02% decrease of -2m year over year
  • Aquestive Therapeutics Inc Long-Term Debt for the last 12 months ending December 12, 2018 was $43m a -4.02% decrease of -2m year over year
  • Aquestive Therapeutics Inc Annual Long-Term Debt for 2018 was $43m a -6.82% decrease of -3m from 2017
  • Aquestive Therapeutics Inc Annual Long-Term Debt for 2017 was $46m a 15.07% increase of 7m from 2016
  • Aquestive Therapeutics Inc Annual Long-Term Debt for 2016 was $39m a 84.67% increase of 33m from 2015
Other Cash Flow Metrics:
  • Aquestive Therapeutics Inc Cash Flow from Operations for the quarter ending September 09, 2018 was $-11m a 35.43% decrease of -4m year over year
  • Aquestive Therapeutics Inc Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-6m a 59.44% decrease of -4m year over year
  • Aquestive Therapeutics Inc Total Revenue for the quarter ending December 12, 2018 was $17m a -39.15% decrease of -7m year over year
View Chart On Koyfin

Quarterly AQST Long-Term Debt Data

12/2018$43m
09/2018$44m
06/2018$45m
03/2018$44m
12/2017$46m

Annual AQST Long-Term Debt Data

2018$43m
2017$46m
2016$39m
2005$6m